

Christian Klein

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1242106/christian-klein-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229
papers

12,586
citations

49
h-index

109
g-index

304
ext. papers

14,901
ext. citations

6.2
avg, IF

5.92
L-index

#	Paper	IF	Citations
229	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. <i>2022</i> , 10,		1
228	Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.. <i>Theranostics</i> , 2022 , 12, 1373-1387	12.1	1
227	Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.. <i>Oncolmmunology</i> , 2022 , 11, 2039432	7.2	3
226	Fibroblast Activation Protein Targeted Photodynamic Therapy Selectively Kills Activated Skin Fibroblasts from Systemic Sclerosis Patients and Prevents Tissue Contraction. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
225	Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist. <i>Blood</i> , 2021 , 138, 1178-1178	2.2	1
224	A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis. <i>AAPS Journal</i> , 2021 , 24, 7	3.7	2
223	Disparity in Peripheral and Renal B-cell Depletion with Rituximab in Systemic Lupus Erythematosus: an Opportunity for Obinutuzumab?. <i>Rheumatology</i> , 2021 ,	3.9	1
222	A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021 , 99, 832-843	4.6	4
221	DNA hypomethylating agents increase activation and cytolytic activity of CD8 T cells. <i>Molecular Cell</i> , 2021 , 81, 1469-1483.e8	17.6	19
220	Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. <i>Lung Cancer</i> , 2021 , 155, 10-19	5.9	3
219	Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies 2021 , 9,		5
218	The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. <i>Arthritis and Rheumatology</i> , 2021 , 73, 826-836	9.5	11
217	Anti-CD20 treatment for B-cell malignancies: current status and future directions. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 161-181	5.4	6
216	Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN γ /CXCL10-dependent peripheral T cell recruitment in humanized murine model. <i>PLoS ONE</i> , 2021 , 16, e0241091	3.7	9
215	A modular and controllable T cell therapy platform for acute myeloid leukemia. <i>Leukemia</i> , 2021 , 35, 2243-2254	11.7	4
214	Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. <i>MAbs</i> , 2021 , 13, 1967714	6.6	6
213	Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies. <i>Oncolmmunology</i> , 2021 , 10, 1869389	7.2	3

212	From Degraders to Molecular Glues: New Ways of Breaking Down Disease-Associated Proteins 2021 , 47-85		1
211	Discovery and Development of Emicizumab (HEMLIBRA [®]): A Humanized Bispecific Antibody to Coagulation Factors IXa and X with a Factor VIII Cofactor Activity 2021 , 221-248		
210	Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. <i>Nature Communications</i> , 2021 , 12, 1237	17.4	10
209	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody. <i>Blood</i> , 2021 ,	2.2	7
208	Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. <i>Blood Advances</i> , 2021 , 5, 2935-2944	7.8	0
207	Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , 2021 , 5, 2945-2957	7.8	1
206	Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells. <i>Journal of Immunology</i> , 2021 , 207, 493-504	5.3	1
205	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , 2021 , 10,	8.9	10
204	Targeting of fibroblast activation protein in rheumatoid arthritis patients: imaging and ex vivo photodynamic therapy. <i>Rheumatology</i> , 2021 ,	3.9	3
203	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. <i>MABs</i> , 2021 , 13, 1913791	6.6	6
202	Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo. <i>MABs</i> , 2020 , 12, 1834818	6.6	1
201	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. <i>Cancers</i> , 2020 , 12,	6.6	7
200	The PET-Tracer Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. <i>Cancer Research</i> , 2020 , 80, 2903-2913	10.1	17
199	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	116
198	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer 2020 , 8,		18
197	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. <i>Nature Communications</i> , 2020 , 11, 3196	17.4	17
196	CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γ cytokine stimulation via PI3K/mTOR axis. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 501-512	7.4	6
195	Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 29-30	2.2	0

194	653 Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release 2020 ,		2
193	RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies. <i>Blood</i> , 2020 , 136, 40-40	2.2	3
192	Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL). <i>Blood</i> , 2020 , 136, 23-24	2.2	0
191	141 PBMC-based cancer vaccines generated with microfluidics squeezing demonstrate synergistic and durable tumor reduction in combination with PD1 checkpoint and FAP targeted IL-2 variants 2020 , 8, A155-A155		1
190	Abstract 2270: RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells 2020 ,		5
189	Long-Term Results from a Phase 1b Study of Avadomide in Combination with Obinutuzumab in Patients with Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 41-42	2.2	2
188	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. <i>Oncotarget</i> , 2020 , 11, 3035-3047	3.3	1
187	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 541-551	11.5	34
186	Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity. <i>Frontiers in Oncology</i> , 2020 , 10, 575737	5.3	14
185	Targeted photodynamic therapy selectively kills activated fibroblasts in experimental arthritis. <i>Rheumatology</i> , 2020 , 59, 3952-3960	3.9	7
184	CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins. <i>MAbs</i> , 2020 , 12, 1840709	6.6	0
183	L4 Synthetic agonistic receptor-activating BiTEs β modular platform for the efficient targeting of acute myeloid leukemia 2020 , 8, A2.2-A3		
182	P06.01 Bispecific antibody-driven synthetic agonistic receptor β transduced T cells mediate specific and conditional therapy in melanoma cancer models 2020 , 8, A41.2-A42		
181	Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. <i>Lancet Haematology, the</i> , 2020 , 7, e649-e659	14.6	12
180	L2 In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific CD20-TCB antibody 2020 , 8, A1.2-A1		
179	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2371-2381	6.1	2
178	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. <i>Frontiers in Immunology</i> , 2019 , 10, 1943	8.4	8
177	P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. <i>Protein Engineering, Design and Selection</i> , 2019 , 32, 207-218	1.9	3

176	DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity. <i>MABs</i> , 2019 , 11, 1402-1414	6.6	6
175	Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab. <i>Scientific Reports</i> , 2019 , 9, 13675	4.9	3
174	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	92
173	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4634-4643	12.9	30
172	Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. <i>MABs</i> , 2019 , 11, 621-631	6.6	22
171	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019 , 133, 1964-1976	2.2	72
170	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019 , 133, 2765-2775	2.2	42
169	Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 5890-5900	12.9	17
168	PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species. <i>Journal of Pharmaceutical Sciences</i> , 2019 , 108, 3729-3736	3.9	2
167	Ocrelizumab: A New Generation of anti-CD20 mAb for Treatment of Multiple Sclerosis 2019 , 169-199		
166	Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. <i>Cancer Immunology Research</i> , 2019 , 7, 2036-2051	12.5	24
165	Abstract 1552: A novel PD1-IL2v immunocytokine for preferential cis-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism 2019 ,		3
164	Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 3963-3963	2.2	1
163	PF207 TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN. <i>HemaSphere</i> , 2019 , 3, 56	0.3	
162	Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide. <i>Blood</i> , 2019 , 134, 4450-4450	2.2	2
161	Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model. <i>Circulation</i> , 2019 , 139, 2049-2063	16.7	29
160	Boosting T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. <i>OncImmunology</i> , 2019 , 8, 1554175	7.2	30
159	Engineering therapeutic bispecific antibodies using CrossMab technology. <i>Methods</i> , 2019 , 154, 21-31	4.6	51

158	High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. <i>British Journal of Cancer</i> , 2019 , 120, 79-87	8.7	18
157	The PI3K-selective inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. <i>Journal of Immunology</i> , 2018 , 200, 2304-2312	5.3	12
156	New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. <i>British Journal of Haematology</i> , 2018 , 180, 808-820	4.5	26
155	Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2018 , 24, 3325-3333	12.9	31
154	Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia 2018 , 245-289		
153	Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. <i>Rheumatology</i> , 2018 , 57, 737-747	3.9	16
152	CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2018 , 24, 4785-4797	12.9	84
151	Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1482-1485	1.9	7
150	A transcriptionally and functionally distinct PD-1 CD8 T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. <i>Nature Medicine</i> , 2018 , 24, 994-1004	50.5	440
149	Abstract 1788: Enhanced in vitro/in vivo cytotoxicity against Burkitt lymphoma/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu- anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab 2018 ,		2
148	Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma. <i>Blood</i> , 2018 , 132, 5381-5381	2.2	
147	GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. <i>Haematologica</i> , 2018 , 103, e78-e81	6.6	9
146	Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study. <i>Oncotarget</i> , 2018 , 9, 7162-7174	3.3	10
145	A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. <i>Journal of Autoimmunity</i> , 2018 , 95, 1-14	15.5	48
144	p95HER2-T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	40
143	Variable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly. <i>Protein Engineering, Design and Selection</i> , 2018 , 31, 289-299	1.9	13
142	Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. <i>BioMed Research International</i> , 2018 , 2018, 1023490	3	12
141	Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. <i>Onc Immunology</i> , 2017 , 6, e1277306	7.2	126

140	A human immunodeficiency syndrome caused by mutations in CARMIL2. <i>Nature Communications</i> , 2017 , 8, 14209	17.4	79
139	A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. <i>Advances in Therapy</i> , 2017 , 34, 324-356	4.1	79
138	Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. <i>Cancer Cell</i> , 2017 , 31, 396-410	24.3	180
137	Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. <i>Rheumatology</i> , 2017 , 56, 1227-1237	3.9	78
136	A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. <i>Leukemia</i> , 2017 , 31, 1611-1621	10.7	23
135	Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. <i>EMBO Molecular Medicine</i> , 2017 , 9, 985	12	4
134	Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. <i>Blood</i> , 2017 , 129, 2636-2644	2.2	58
133	Combination therapy with the type II anti-CD20 antibody obinutuzumab. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1145-1162	5.9	4
132	Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2017 , 28, iii151	10.3	17
131	PD-1 IMMUNE CHECKPOINT BLOCKADE IMPROVES ANTI-CD20 BASED IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2017 , 35, 257-258	1.3	
130	Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab. <i>Leukemia and Lymphoma</i> , 2017 , 58, 699-707	1.9	14
129	A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 129-140	7.4	80
128	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti-Fibroblast Activation Protein Antibody. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 151-155	8.9	26
127	Abstract 3629: Engineering a novel asymmetric head-to-tail 2+1 T-cell bispecific (2+1 TCB) IgG antibody platform with superior T-cell killing compared to 1+1 asymmetric TCBs 2017 ,		3
126	Abstract 3634: A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells 2017 ,		3
125	Abstract 3658: Dendritic cells dictate the responsiveness of PD-L1 blockade in cancer 2017 ,		2
124	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. <i>Oncotarget</i> , 2017 , 8, 113895-113909	3.3	11
123	Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products. <i>Protein Engineering, Design and Selection</i> , 2017 , 30, 649-656	1.9	9

122	Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. <i>Protein Engineering, Design and Selection</i> , 2016 , 29, 457-466	1.9	145
121	TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. <i>Protein Engineering, Design and Selection</i> , 2016 , 29, 467-475	1.9	16
120	CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. <i>Oncolmmunology</i> , 2016 , 5, e1203498	7.2	65
119	OP0159 Improving B-Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Resistance To Rituximab and The Potential of Obinutuzumab. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 116.1-116	2.4	2
118	RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 946-57	6.1	67
117	The use of CrossMAb technology for the generation of bi- and multispecific antibodies. <i>MAbs</i> , 2016 , 8, 1010-20	6.6	86
116	Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin $\alpha 4 \beta 1$. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 467-72	8.9	28
115	XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. <i>MAbs</i> , 2016 , 8, 811-27	6.6	25
114	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , 2016 , 14, 1748-1760	10.6	69
113	Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (Tavi6) targeting VEGF-A and angiopoietin-2. <i>MAbs</i> , 2016 , 8, 562-73	6.6	15
112	A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 3286-97	12.9	185
111	Activation of cytomegalovirus-specific CD8 T-cell response by antibody-mediated peptide-major histocompatibility class I complexes. <i>Oncolmmunology</i> , 2016 , 5, e1052930	7.2	
110	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. <i>Oncolmmunology</i> , 2016 , 5, e1062969	7.2	21
109	Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry. <i>MAbs</i> , 2016 , 8, 49-55	6.6	21
108	CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies. <i>Blood</i> , 2016 , 128, 1836-1836	2.2	17
107	The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models. <i>Blood</i> , 2016 , 128, 4178-4178	2.2	2
106	A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2130-42	6.1	10
105	Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. <i>EMBO Molecular Medicine</i> , 2016 , 8, 1265-1288	12	111

104	Solution structure and binding specificity of the p63 DNA binding domain. <i>Scientific Reports</i> , 2016 , 6, 26707	4.9	13
103	Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. <i>Journal of Immunotherapy</i> , 2016 , 39, 279-89	5	18
102	In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing. <i>Clinical Cancer Research</i> , 2016 , 22, 4417-27	12.9	47
101	Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388). <i>European Journal of Haematology</i> , 2016 , 97, 461-470	3.8	21
100	Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>Journal of Autoimmunity</i> , 2015 , 56, 66-80	15.5	57
99	Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 778-83	8.9	59
98	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. <i>Cancer Immunology Research</i> , 2015 , 3, 1344-55	12.5	197
97	Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules. <i>Cancer Immunology Research</i> , 2015 , 3, 764-76	12.5	13
96	Obinutuzumab in hematologic malignancies: lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015 , 41, 784-92	14.4	37
95	How to outsmart NK cell tolerance. <i>Onc Immunology</i> , 2015 , 4, e1016708	7.2	7
94	Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin lymphomas: a glycoengineered type II CD20 antibody. <i>Oncology Research and Treatment</i> , 2015 , 38, 185-92	2.8	36
93	Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, 364	9.7	29
92	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. <i>British Journal of Haematology</i> , 2015 , 171, 1763-73	4.5	68
91	Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. <i>International Journal of Cancer</i> , 2015 , 137, 2234-42	7.5	30
90	Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. <i>Journal of Biological Chemistry</i> , 2015 , 290, 5424-37	5.4	22
89	Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers. <i>Blood Cancer Journal</i> , 2015 , 5, e367	7	11
88	A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys. <i>Blood</i> , 2015 , 126, 2998-2998	2.2	3
87	CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo. <i>Blood</i> , 2015 , 126, 4157-4157	2.2	2

86	Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins. <i>Blood</i> , 2015 , 126, 1550-1550	2.2	
85	Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. <i>Journal of Immunology</i> , 2014 , 192, 2252-60	5.3	109
84	A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. <i>Journal of Biological Chemistry</i> , 2014 , 289, 18693-706	5.4	43
83	KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. <i>Journal of Immunology</i> , 2014 , 192, 5618-24	5.3	56
82	S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer 2014 , 2,		7
81	Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma 2014 , 1695-1732		2
80	Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2151-5160	1.9	40
79	Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation. <i>Chemistry and Biology</i> , 2014 , 21, 357-68		6
78	Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodies in vitro and in vivo 2014 ,		2
77	Abstract 650: KIR/HLA interactions negatively affect rituximab, but not GA101 (obinutuzumab)-induced ADCC 2014 ,		2
76	Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo. <i>Blood</i> , 2014 , 124, 1765-1765	2.2	4
75	Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?. <i>Blood</i> , 2014 , 124, 1980-1980	2.2	2
74	The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab. <i>Blood</i> , 2014 , 124, 3342-3342	2.2	4
73	ADCC Induced By Monoclonal Anti-CD20 Antibodies in a 3D Follicular Lymphoma model : Signaling and Spatial Localization. <i>Blood</i> , 2014 , 124, 3114-3114	2.2	
72	Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity. <i>Blood</i> , 2014 , 124, 1780-1780	2.2	
71	Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. <i>Journal of Immunology</i> , 2013 , 191, 3634-40	5.3	24
70	GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2500-5	1.9	48
69	Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2013 , 37, 440-6	2.7	21

68	Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. <i>PLoS ONE</i> , 2013 , 8, e61953	3.7	26
67	Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. <i>MABs</i> , 2013 , 5, 22-33	6.6	193
66	Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2013 , 4, 660-5	4.3	46
65	Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2031-42	6.1	243
64	Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. <i>Clinical Cancer Research</i> , 2013 , 19, 6730-40	12.9	150
63	Combining chemotherapeutic agents and netrin-1 interference potentiates cancer cell death. <i>EMBO Molecular Medicine</i> , 2013 , 5, 1821-34	12	28
62	Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. <i>Blood Cancer Journal</i> , 2013 , 3, e131	7	35
61	A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. <i>Oncogene</i> , 2013 , 32, 5593-601	9.2	45
60	Response to: monoclonal antibodies targeting CD20. <i>MABs</i> , 2013 , 5, 337-8	6.6	10
59	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , 2013 , 122, 3482-91	2.2	172
58	Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies. 2013 ,		2
57	Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer. <i>Blood</i> , 2013 , 122, 2278-2278	2.2	7
56	Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies. <i>Blood</i> , 2013 , 122, 4412-4412	2.2	4
55	A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. <i>PLoS ONE</i> , 2013 , 8, e54923	3.7	57
54	Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. <i>Archives of Biochemistry and Biophysics</i> , 2012 , 526, 206-18	4.1	39
53	Bispecific antibody derivatives based on full-length IgG formats. <i>Methods in Molecular Biology</i> , 2012 , 901, 247-63	1.4	15
52	Glycoengineering of Therapeutic Antibodies. <i>Arzneimittelforschung</i> , 2012 , 62, S4-S5		
51	Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. <i>MABs</i> , 2012 , 4, 653-63	6.6	130

50	Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. <i>Protein Engineering, Design and Selection</i> , 2012 , 25, 551-9	1.9	32
49	Abstract LB-236: M4-3-ML2, a novel glycoengineered humanized IgG1 antibody, targeting a membrane-proximal epitope of MCSP/CSPG4 exhibits potent ADCC induction in vitro and in vivo anti-tumoral efficacy in disseminated melanoma models 2012 ,		2
48	Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1991-2005	15.9	295
47	Obinutuzumab (GA101) Displays Higher Efficiency Than Rituximab in a Follicular Lymphoma 3D Model. <i>Blood</i> , 2012 , 120, 4868-4868	2.2	
46	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. <i>Blood</i> , 2011 , 117, 510-8	2.2	49
45	Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. <i>Blood</i> , 2011 , 118, 358-67	2.2	168
44	CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. <i>Blood</i> , 2011 , 118, 5178-88	2.2	36
43	Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2011 , 152, 295-306	4.5	103
42	A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. <i>Microcirculation</i> , 2011 , 18, 598-607	2.9	24
41	Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 11187-92	11.5	289
40	Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 178-85	6.1	106
39	Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines. <i>PLoS ONE</i> , 2011 , 6, e16596	3.7	18
38	BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. <i>Journal of Biological Chemistry</i> , 2010 , 285, 3439-50	5.4	64
37	Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. <i>Blood</i> , 2010 , 115, 4393-402	2.2	635
36	Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates. <i>Blood</i> , 2010 , 116, 3373-3374	2.2	8
35	Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263. <i>Blood</i> , 2010 , 116, 3915-3915	2.2	1
34	Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101 vs. the Type I CD20 Antibodies Rituximab and Ofatumumab. <i>Blood</i> , 2010 , 116, 3925-3925	2.2	5
33	CD40 Stimulation Sensitizes CLL Cells to CD20-Triggered Cell Death by Rituximab and GA101 Via a Different Mechanism. <i>Blood</i> , 2010 , 116, 3979-3979	2.2	

32	Enhanced Killing of Human B Lymphoma Targets by Combined Use of Cytokine Induced Killer (CIK) Cultures and Anti-CD20 Antibodies. <i>Blood</i> , 2010 , 116, 4285-4285	2.2	
31	Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2010 , 116, 2459-2459	2.2	
30	Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2. <i>Blood</i> , 2010 , 116, 4304-4304	2.2	
29	Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. <i>Clinical Cancer Research</i> , 2009 , 15, 5811-9	12.9	9
28	Antikörper Die Krebsmedikamente. Gezielt wirksame Biomedizin. <i>Chemie in Unserer Zeit</i> , 2009 , 43, 328-338	0.2	1
27	Short-hairpin-RNA-mediated silencing of Fucosyltransferase 8 in Chinese-hamster ovary cells for the production of antibodies with enhanced antibody immune effector function. <i>Biotechnology and Applied Biochemistry</i> , 2009 , 53, 31-7	2.8	22
26	Targeting the p53/MDM2 Pathway for Cancer Therapy 2008 , 19-56		
25	An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 4382-7	8.3	34
24	A Novel Synthesis of Highly Substituted Perhydropyrrolizines, Perhydroindolizines, and Pyrrolidines: Inhibition of the Peptidyl-Prolyl cis/trans Isomerase (PPIase) Pin1. <i>Helvetica Chimica Acta</i> , 2007 , 90, 217-259	2	18
23	The low molecular weight proteome of Halobacterium salinarum. <i>Journal of Proteome Research</i> , 2007 , 6, 1510-8	5.6	60
22	GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.. <i>Blood</i> , 2007 , 110, 2348-2348	2.2	12
21	p53--a natural cancer killer: structural insights and therapeutic concepts. <i>Angewandte Chemie - International Edition</i> , 2006 , 45, 6440-60	16.4	85
20	p53 Ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte. <i>Angewandte Chemie</i> , 2006 , 118, 6590-6611	3.6	10
19	WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. <i>Journal of Biological Chemistry</i> , 2006 , 281, 8600-6	5.4	179
18	214 POSTER Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-1 receptor. <i>European Journal of Cancer, Supplement</i> , 2006 , 4, 66-67	1.6	10
17	Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.. <i>Blood</i> , 2006 , 108, 229-229	2.2	30
16	Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. <i>Angewandte Chemie - International Edition</i> , 2005 , 44, 5247-51	16.4	42
15	Kooperative Bindung von p53 an DNA: Regulation durch Protein-Protein-Wechselwirkung unter Bildung einer doppelten Salzbrücke. <i>Angewandte Chemie</i> , 2005 , 117, 5381-5386	3.6	5

14	In vitro folding and characterization of the p53 DNA binding domain. <i>Biological Chemistry</i> , 2004 , 385, 95-102	4.5	5
13	Targeting the p53-MDM2 interaction to treat cancer. <i>British Journal of Cancer</i> , 2004 , 91, 1415-9	8.7	158
12	In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. <i>Science</i> , 2004 , 303, 844-8	33.3	3663
11	Backbone ¹ H, ¹³ C and ¹⁵ N resonance assignments for the 25.8 kDa DNA binding domain of the human p63 protein. <i>Journal of Biomolecular NMR</i> , 2003 , 26, 377-8	3	5
10	The N-terminal domain of p53 is natively unfolded. <i>Journal of Molecular Biology</i> , 2003 , 332, 1131-41	6.5	203
9	p53 contains large unstructured regions in its native state. <i>Journal of Molecular Biology</i> , 2002 , 322, 917-27.5		214
8	NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. <i>Journal of Biological Chemistry</i> , 2001 , 276, 49020-7	5.4	67
7	High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53. <i>Journal of Biological Chemistry</i> , 2001 , 276, 37390-401	5.4	56
6	Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. <i>Biochemistry</i> , 2001 , 40, 336-44	3.2	248
5	Isolation and characterization of glycosylphosphatidylinositol-anchored, mucin-like surface glycoproteins from bloodstream forms of the freshwater-fish parasite <i>Trypanosoma carassii</i> . <i>Biochemical Journal</i> , 2000 , 345, 693	3.8	9
4	Proteophosphoglycans of <i>Leishmania mexicana</i> . Identification, purification, structural and ultrastructural characterization of the secreted promastigote proteophosphoglycan pPPG2, a stage-specific glycoisoform of amastigote aPPG. <i>Biochemical Journal</i> , 1999 , 344 Pt 3, 775-86	3.8	15
3	Proteophosphoglycans of <i>Leishmania mexicana</i> . Molecular cloning and characterization of the <i>Leishmania mexicana</i> ppg2 gene encoding the proteophosphoglycans aPPG and pPPG2 that are secreted by amastigotes and promastigotes. <i>Biochemical Journal</i> , 1999 , 344 Pt 3, 787-95	3.8	21
2	Proteophosphoglycans of <i>Leishmania mexicana</i> . <i>Biochemical Journal</i> , 1999 , 344, 775	3.8	9
1	Proteophosphoglycans of <i>Leishmania mexicana</i> . <i>Biochemical Journal</i> , 1999 , 344, 787	3.8	8